Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.27 +0.39 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
31 32 Next >
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Via Benzinga
Why Is Provention Biosciences (PRVB) Stock Up 25% Today?
Provention Biosciences shares are trending after reporting earnings. PRVB stock is also up 25% on hopes of FDA approval for teplizumab. 
Via InvestorPlace
Tesla Shifts China Factory Workers To US Plant, Complete European Approval For AstraZeneca's COVID-19 Shot, Tesla Eyes Cybertruck Commercialization From Next Year: Top Stories Tuesday, Nov. 01
Bloomberg Tesla Migrates Shanghai Factory Workers To Boost US Plant Production 
Via Benzinga
Sanofi (SNY) Q3 2022 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance Boost
Sanofi stock jumped Friday after the company reported better-than-expected profit. 
Via Investor's Business Daily
Dupixent, Flu Vaccine Demand Boost Sanofi's Q3 Earnings, Lifts Annual Outlook
Via Benzinga
Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech
Via Benzinga
Sanofi: Q3 Earnings Insights
Sanofi (NASDAQ:SNY) reported its Q3 earnings results on Friday, October 28, 2022 at 05:00 AM. Here's what investors need to know about the announcement. Earnings Sanofi beat estimated earnings by... 
Via Benzinga
Earnings Scheduled For October 28, 2022
Companies Reporting Before The Bell • TAL Education (NYSE:TAL) is projected to report quarterly earnings at $0.01 per share on revenue of $242.62 million. 
Via Benzinga
Sanofi's Earnings Outlook
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-10-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an... 
Via Benzinga
3 Dividend Stocks That Could Soar 51% to 58%, According to Wall Street
Two of these three pay especially attractive dividends. 
Via The Motley Fool
US Stock Futures Lower Following Friday's Rally; Tesla In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the... 
Via Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its... 
Via Benzinga
2 High-Yielding Dividend Stocks That Haven't Been This Cheap in Years
Is now the time to buy Sanofi and Intel? 
Via The Motley Fool
3 Red-Hot Stocks That Could Continue to Beat the Market
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product
Via Benzinga
2 Top Healthcare Stocks to Buy Right Now
Healthcare is about as sticky of a business model as you'll find. 
Via The Motley Fool
7 Under-$50 Stocks to Buy to Tap Into a Hidden Bull Market
Those seeking compelling market ideas during this storm may want to consider these relevant under-$50 stocks to buy. 
Via InvestorPlace
2 Stocks Jumping in Thursday's Premarket Trading
Get an early start on the events of the day. 
Via The Motley Fool
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate
Via Benzinga
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
Via Benzinga
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi
San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at... 
Via SBWire
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
Via Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
Via Benzinga
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
Via Benzinga
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients
Via Benzinga
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
Via Benzinga
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.